FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer
SUNNYVALE, Calif., July 23 FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced the appointment of Chris Barys to the position of Chief Operating Officer. Chris previously held the position of Executive VP, Sales and Marketing at FlowCardia and has over 18 years of experience in Medical Devices including the last 2 years at FlowCardia.
Prior to FlowCardia, Mr. Barys served as Vice President of Sales and Marketing for the Peripheral Vascular Systems business for Edwards Lifesciences where he had broad responsibility for this rapidly growing business segment. In his new role at FlowCardia, Mr. Barys will assume responsibility for R&D, Quality, Clinical and Regulatory functions in addition to Sales and Marketing. This move will consolidate all primary "customer touching" functions within the company under Mr. Barys.
"We are excited to have Chris take on this new role at FlowCardia as this is a critical time for the Company," said Wick Goodspeed, President and CEO of FlowCardia. "Since joining FlowCardia he has built a sales and marketing organization that has driven sales of the Company's flagship product, the CROSSER Catheter, to record success."
FlowCardia initiated commercial efforts in February of 2008 and the Company has quickly captured a market leadership position in the CTO recanalization device space. The novel CROSSER Catheter enables peripheral and coronary interventionalists to recanalize CTOs in the central lumen of the artery, allowing physicians to treat patients more definitively with a broader range of therapeutic options like atherectomy, angioplasty and stenting.
"There is a lot of momentum right now at FlowCardia with CROSSER adoption on the rise and a significant increase in sales activity," said Mr. Barys. "FlowCardia is in the midst of rapid growth and I look forward to working with the management team and accelerating operations to keep pace with the unmet clinical need of thousands of patients with CTO's."
About the CROSSER CTO Recanalization Catheter
The CROSSER CTO Recanalization Catheter is a minimally-invasive endovascular device that is delivered to a blockage within an artery using standard guidewire techniques. The doctor then activates the CROSSER Catheter which utilizes high-frequency, mechanical vibration to cross the blockage in the central lumen of the coronary or peripheral artery. Once the CROSSER Catheter passes through the occlusion and a guidewire is advanced distally, physicians can then perform standard atherectomy, balloon angioplasty and/or stent placement to optimize the longer term outcomes. For many patients, this minimally invasive approach to CTO recanalization can eliminate the need for a potentially traumatic bypass procedure or amputation.
FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a portfolio of endovascular CTO recanalization products. Additional information is available on the company's web site: www.flowcardia.com.
PR Contact Info: Mark Page Sr. Director, Marketing FlowCardia, Inc. 408-617-0352 ext.301
SOURCE FlowCardia, Inc.
You May Also Like